History

Menarini Biomarkers Singapore (MBS) was created in 2014 by  Menarini Asia Pacific in Singapore and is fully owned by Menarini Group the biggest Italian Pharma Company with annual revenue of 3.8 Billion Euro (2021). Menarini Group, which was founded in 1886, has over 17,000 employees working in more than 130 countries.

The initial mission of MBS was to identify, develop and validate new biomarkers on circulating human cells for applications in diagnostics. From liquid biopsies, circulating cells such as CFC (circulating fetal cells) or CTC (circulating tumor cells) were captured by specific antibodies developed against novel targets and conjugated to FerroFluid (Menarini-Cell Search Technology) and further selected by sorting as single cells for molecular analysis.

Using this approach, MBS has been able to identify biomarkers on circulating trophoblasts from pregnant women and has established a platform to capture them. This technology will transform prenatal diagnostics.

Mission

MBS aspires to launch a leading and innovative Platform for a non-invasive Cell-Based test suitable for the entire pregnant population. This will help clinicians, at a worldwide level, manage accurate prenatal testing and allow personalized treatments in addressing genetic disorders prenatally. 

An international experienced management team

  • Stephen PhuaChairman of the Board of Directors Bio
  • Luigi RicciardiCEO Bio
  • Thomas Musci, M.D.CMO (Chief Medical Officer) Bio
  • Paola Castagoli, PhDChief Scientist Bio
  • Francesca Romana Grati, Ph.D. , ErCLGChief Genomics Officer (CGO) Bio
  • Anna Doffini, PhDCB-NIPT Project Manager Bio

Contact us




    By clicking the “Send” button, I consent to the processing of the personal data submitted via the form, including any sensitive personal data, for the purposes of managing my request, in line with the Privacy Information Notice and the applicable laws on the protection of personal information.

    (*) Required data and consent: should you not wish to provide them, we will be unable to process your request

    © 2019 | Menarini Biomarkers Singapore (MBS) is a company fully owned by Menarini Group  |  Privacy Policy  |  Cookie Policy